Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-13 8:15 pm Sale | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | SUVRETTA CAPITAL MANAGEMENT, LLC | 5,198,189 6.700% | -2,274,154 (-30.43%) | Filing History |
| 2025-02-13 8:09 pm Sale | 2024-12-31 | 13G | Erasca, Inc. ERAS | SUVRETTA CAPITAL MANAGEMENT, LLC | 12,315,004 4.400% | -1,453,035 (-10.55%) | Filing History |
| 2025-02-13 8:00 pm Purchase | 2024-12-31 | 13G | 89bio, Inc. ETNB | SUVRETTA CAPITAL MANAGEMENT, LLC | 10,202,696 8.500% | 2,211,052 (+27.67%) | Filing History |
| 2025-02-11 8:51 pm Purchase | 2025-02-04 | 13G | Immatics N.V. IMTX | SUVRETTA CAPITAL MANAGEMENT, LLC | 7,881,608 6.500% | 7,881,608 (New Position) | Filing History |
| 2025-02-11 8:45 pm Purchase | 2025-02-07 | 13G | Marinus Pharmaceuticals, Inc. MRNS | SUVRETTA CAPITAL MANAGEMENT, LLC | 3,022,612 5.500% | 917,348 (+43.57%) | Filing History |
| 2025-02-11 8:20 pm Sale | 2024-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | SUVRETTA CAPITAL MANAGEMENT, LLC | 2,105,264 3.800% | -3,358,377 (-61.47%) | Filing History |
| 2025-02-07 5:36 pm Purchase | 2025-02-05 | 13G | PepGen Inc. PEPG | SUVRETTA CAPITAL MANAGEMENT, LLC | 1,660,932 5.100% | 486,611 (+41.44%) | Filing History |
| 2025-02-07 5:16 pm Sale | 2024-12-31 | 13G | PepGen Inc. PEPG | SUVRETTA CAPITAL MANAGEMENT, LLC | 1,174,321 3.600% | -486,611 (-29.30%) | Filing History |
| 2025-01-06 4:50 pm Purchase | 2024-12-27 | 13G | Fulcrum Therapeutics, Inc. FULC | SUVRETTA CAPITAL MANAGEMENT, LLC | 3,404,612 6.300% | 2,221,821 (+187.85%) | Filing History |
| 2024-12-20 4:56 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | SUVRETTA CAPITAL MANAGEMENT, LLC | 714,463 8.600% | 714,463 (New Position) | Filing History |
| 2024-12-04 4:32 pm Purchase | 2024-11-26 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | SUVRETTA CAPITAL MANAGEMENT, LLC | 2,040,365 6.100% | 2,040,365 (New Position) | Filing History |
| 2024-11-18 4:36 pm Purchase | 2024-11-14 | 13D | Benitec Biopharma Inc. BNTC | SUVRETTA CAPITAL MANAGEMENT, LLC | 14,329,937 49.900% | 5,500,884 (+62.30%) | Filing History |
| 2024-11-14 4:28 pm Purchase | 2024-09-30 | 13G | Zura Bio Limited ZURA | SUVRETTA CAPITAL MANAGEMENT, LLC | 4,860,939 7.600% | 2,010,939 (+70.56%) | Filing History |
| 2024-11-14 4:25 pm Sale | 2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC | SUVRETTA CAPITAL MANAGEMENT, LLC | 1,182,791 2.200% | -4,336,090 (-78.57%) | Filing History |
| 2024-11-14 4:18 pm Sale | 2024-09-30 | 13G | Mereo BioPharma Group plc MREO | SUVRETTA CAPITAL MANAGEMENT, LLC | 0 0.000% | -36,854,190 (Position Closed) | Filing History |
| 2024-11-14 3:57 pm Purchase | 2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV | SUVRETTA CAPITAL MANAGEMENT, LLC | 4,328,904 9.990% | 1,644,899 (+61.29%) | Filing History |
| 2024-11-14 3:52 pm Sale | 2024-09-30 | 13G | Cogent Biosciences, Inc. COGT | SUVRETTA CAPITAL MANAGEMENT, LLC | 0 0.000% | -5,481,034 (Position Closed) | Filing History |
| 2024-11-14 3:41 pm Sale | 2024-09-30 | 13G | Terns Pharmaceuticals, Inc. TERN | SUVRETTA CAPITAL MANAGEMENT, LLC | 0 0.000% | -5,837,126 (Position Closed) | Filing History |
| 2024-10-22 3:32 pm Purchase | 2024-08-28 | 13G | ProKidney Corp. PROK | SUVRETTA CAPITAL MANAGEMENT, LLC | 13,198,766 10.470% | 8,473,418 (+179.32%) | Filing History |
| 2024-10-17 9:21 pm Purchase | 2024-02-06 | 13G | 89bio, Inc. ETNB | SUVRETTA CAPITAL MANAGEMENT, LLC | 7,991,644 7.500% | 3,103,210 (+63.48%) | Filing History |